PF 6427878

Drug Profile

PF 6427878

Alternative Names: PF-06427878; PF-6427878

Latest Information Update: 19 Sep 2016

Price : $50

At a glance

  • Originator Pfizer
  • Class Antihyperlipidaemics
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hyperlipidaemia

Most Recent Events

  • 01 Aug 2016 Pfizer initiates a phase I trial in Healthy volunteers in USA (PO, Suspension) (NCT02855177)
  • 01 Feb 2016 Pfizer completes a phase I pharmacokinetic trial in Healthy volunteers in Belgium (PO) (NCT02391623)
  • 01 May 2015 Pfizer initiates enrolment in a phase I pharmacokinetic trial in Healthy male volunteers in USA (NCT02410525)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top